Welcome to our dedicated page for Fate Therapeutics news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutics stock.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's innovative approach leverages induced pluripotent stem cell (iPSC) technology to create off-the-shelf, engineered NK- and T-cell product candidates designed to deliver multiple therapeutic mechanisms to patients.
Fate Therapeutics' proprietary iPSC product platform enables the mass production of multiplexed-engineered cell products that are uniform in composition and can be stored for off-the-shelf availability. This platform allows for the efficient manufacture of well-defined cell therapies that can be used in combination with other treatments, significantly overcoming the limitations of patient- or donor-sourced cells.
Recent highlights include the initiation of patient enrollment in the Phase 1 study of FT522, an ADR-armed, CD19-targeted CAR NK cell program for B-cell lymphoma. Additionally, the FDA has cleared the IND application for FT825/ONO-8250 in solid tumors, marking a key milestone in the company's collaboration with ONO Pharmaceutical. The expansion of the iPSC product platform into autoimmunity with FT819, targeting systemic lupus erythematosus, further underscores Fate Therapeutics' commitment to addressing complex diseases.
The company's financial health remains robust, bolstered by recent funding efforts, including the sale of shares and pre-funded warrants to institutional investors. Fate Therapeutics continues to lead in the field of cellular immunotherapies, with a strong pipeline of product candidates and an intellectual property portfolio comprising over 500 issued patents and 500 pending patent applications.
Headquartered in San Diego, CA, Fate Therapeutics is dedicated to advancing its clinical programs and providing innovative treatments to improve patient outcomes. For more information, please visit www.fatetherapeutics.com.
Fate Therapeutics announced positive interim results from its Phase 1 study of FT516 in combination with rituximab for relapsed/refractory B-cell lymphoma. Of the four patients evaluable, three achieved an objective response, including two complete responses. Importantly, FT516 was well-tolerated with no severe adverse events and no cases of cytokine release syndrome. The study indicates the potential for FT516 to be administered in an outpatient setting, potentially expanding treatment options for patients. A fourth dose cohort of FT516 is planned as part of ongoing research.
Fate Therapeutics, Inc. (NASDAQ: FATE) will host a virtual event titled “The Power of hnCD16” on December 4, 2020, at 4:30 PM EDT. This event will focus on the unique therapeutic features of the hnCD16 Fc receptor, crucial in its engineered NK cell therapies. The hnCD16 is designed to enhance antibody-dependent cellular cytotoxicity, effectively targeting and killing cancer cells. The event will be accessible via the company's website, with an archived version available afterward. Fate Therapeutics specializes in developing off-the-shelf cellular immunotherapies for cancer and immune disorders.
Fate Therapeutics, Inc. (NASDAQ: FATE) has announced its participation in three upcoming investor conferences. The events include the Stifel Healthcare Virtual Conference on November 17, 2020, Jefferies Global Healthcare Virtual Conference on November 19, 2020, and Evercore ISI HealthCONx Virtual Conference on December 1, 2020. Each event will feature a live webcast available on the company's investor relations section. Fate Therapeutics focuses on developing cellular immunotherapies for cancer and immune disorders, utilizing its proprietary iPSC platform.
Fate Therapeutics reported encouraging advancements in its clinical trials for its iPSC-derived NK cell therapies. The Phase 1 study of FT596 has expanded, treating patients with B-cell lymphoma and now chronic lymphocytic leukemia. Initial patients have also been treated with FT516 in combination with avelumab for solid tumors. The company has initiated enrollment for FT538, a CRISPR-edited therapy, targeting acute myeloid leukemia and multiple myeloma. Financially, total revenue for Q3 2020 was $7.6 million, while R&D and G&A expenses were $30.7 million and $8.4 million, respectively.
Fate Therapeutics (NASDAQ: FATE) announced the acceptance of four oral presentations at the 62nd American Society of Hematology Annual Meeting, to be held virtually from December 5-8, 2020. These presentations will focus on the company’s iPSC-derived NK cell therapies, particularly FT596, in clinical trials for B-cell lymphoma. Additionally, an investor event titled "The Power of hnCD16" is scheduled for December 4, showcasing the functionality of the hnCD16 Fc receptor, which enhances tumor-targeting capabilities. The company aims to develop scalable, off-the-shelf cancer immunotherapies.
Fate Therapeutics, Inc. (NASDAQ: FATE) will host a conference call on November 5, 2020, at 5:00 p.m. ET to discuss its third quarter 2020 financial results and provide a corporate update.
Participants can join by calling (877) 303-6235 domestically or (631) 291-4837 internationally using conference ID 1060606.
The live audio webcast will be accessible via the company's website, with an archived version available two hours post-event.
Fate Therapeutics (NASDAQ: FATE) announced that five abstracts for its iPSC product platform will be presented at the upcoming SITC annual meeting from November 9-14, 2020. The abstracts highlight clinical data from 15 patients in the Phase 1 trial of FT500 for advanced solid tumors. This includes a dose-expansion stage for patients with non-small cell lung cancer or Hodgkin lymphoma. The presentation topics include targeting tumor antigens and the efficacy of iPSC-derived NK cell immunotherapy. Fate's iPSC platform aims to create effective, off-the-shelf therapies, supported by a robust patent portfolio.
Fate Therapeutics (NASDAQ: FATE) announced its participation in the Jefferies Cell Therapy Virtual Summit on October 6, 2020, at 2:30 p.m. E.T.. The management will engage in a fireside chat to discuss advancements in their programmed cellular immunotherapies for cancer and immune disorders. A live webcast of the presentation will be accessible via the company's investor relations webpage. Fate Therapeutics is known for its innovative iPSC product platform, developing both cancer immunotherapies and treatments for immune disorders.
Fate Therapeutics (NASDAQ: FATE) announced its participation in several investor conferences scheduled for September 2020, including the Baird Global Healthcare Conference and the Citi 15th Annual BioPharma Conference. The company, known for its innovative cellular immunotherapies for cancer and immune disorders, is set to present at multiple venues over the course of the month. Interested investors can access live webcasts on the company’s investor relations website, with archived replays available shortly thereafter.
Fate Therapeutics reported encouraging early clinical data for its FT596 product in a patient with refractory diffuse large B-cell lymphoma, showing a partial response with significant tumor size reduction and no serious side effects. The company has cleared multiple IND applications for its innovative iPSC-derived therapies, including FT538 for AML and FT819 for B-cell leukemias, and continues to advance its collaboration with Janssen to develop CAR NK and CAR T-cell therapies. As of June 30, 2020, Fate Therapeutics had $533 million in cash and investment resources.
FAQ
What is the current stock price of Fate Therapeutics (FATE)?
What is the market cap of Fate Therapeutics (FATE)?
What does Fate Therapeutics specialize in?
What is the iPSC product platform?
What are the recent achievements of Fate Therapeutics?
What is the financial condition of Fate Therapeutics?
Where is Fate Therapeutics headquartered?
How does Fate Therapeutics address the limitations of patient- or donor-sourced cells?
What is the significance of FT522 and FT825/ONO-8250?
What diseases does Fate Therapeutics aim to treat?
What makes Fate Therapeutics' iPSC product platform unique?
How can I learn more about Fate Therapeutics?
